Poseida Therapeutics Inc Forecast, price target & analysts
Poseida Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Poseida Therapeutics Inc Classifications & Recommendation:
Poseida Therapeutics Inc Price Target
| Target Price | $9.18 |
| Price | $9.50 |
| Deviation |
3.37%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Poseida Therapeutics Inc 2026 .
The average Poseida Therapeutics Inc target price is $9.18.
This is
3.37%
register free of charge
$9.45
0.53%
register free of charge
$9.09
4.32%
register free of charge
|
|
| A rating was issued by 10 analysts: 0 Analysts recommend Poseida Therapeutics Inc to buy, 7 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Poseida Therapeutics Inc stock has an average upside potential 2026 of
3.37%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2027
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 64.70 | 150.06 |
| 50.42% | 131.93% | |
| EBITDA Margin | -191.48% | -83.48% |
| 356.58% | 56.40% | |
| Net Margin | -190.77% | -62.90% |
| 289.00% | 67.03% |
6 Analysts have issued a sales forecast Poseida Therapeutics Inc 2024 . The average Poseida Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Poseida Therapeutics Inc EBITDA forecast 2024. The average Poseida Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2023 | $-124m | 126.37% |
|---|---|---|
| 2024 |
$-125m
1.11%
Unlock
|
|
EBITDA Margin
| 2023 | -191.48% | 356.58% |
|---|---|---|
| 2024 |
-83.48%
56.40%
Unlock
|
|
7 Poseida Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Poseida Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2027
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.37 | -0.97 |
| 53.93% | 29.20% | |
| P/E | negative |
7 Analysts have issued a Poseida Therapeutics Inc forecast for earnings per share. The average Poseida Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Poseida Therapeutics Inc...
Current Poseida Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Locked
➜
Locked
|
Locked | Nov 26 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 26 2024 |
| William Blair |
Locked
➜
Locked
|
Locked | Nov 26 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 08 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 30 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 17 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
BTIG:
Locked
➜
Locked
|
Nov 26 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 26 2024 |
|
Locked
William Blair:
Locked
➜
Locked
|
Nov 26 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 15 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 08 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 30 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 17 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
